VRTX - Quick Take - Not On Our 2026 Bingo Card: ~$10B Acquisition of Endocrinology Focused Crinetics

Research evidence excerpt

VRTX - Quick Take - Not On Our 2026 Bingo Card: ~$10B Acquisition of Endocrinology Focused Crinetics

data,

Reasons for this report and if its efficacy and safety profile are confirmed in Phase 3, the transaction should prove

strategically and financially attractive for Vertex.

✓ Quick Reaction to Newsflow/Volatility

While endocrinology adds a new commercial pillar, we are confident in the company's ability

to successfully commercialize rare-disease therapies and maximize the value of Crinetics'

assets. In addition, the endocrinology infrastructure built through this acquisition could create

future commercial synergies with Vertex's type 1 diabetes (T1D) portfolio, a key long-term

area of investment, while the broader Crinetics pipeline provides additional upside optionality

beyond the two lead programs.

Deal Rationale

On the call, VRTX provided more color on the strategic rationale behind this deal. Most

notable takeaways, in our view, were the following:

• Calculated bet on atumelnant in CAH: Vertex views this as a multi-billion-dollar

opportunity and indicated that the asset was the primary driver of its interest in acquiring

Crinetics. Management believes atumelnant has the potential to deliver the longstanding

"holy grail" in CAH treatment (effective androgen control while maintaining physiologic

glucocorticoid dosing), a combination that has remained elusive with both legacy

therapies and Neurocrine's (NBIX, BUY) Crenessity. The key risk, in our view, is the

competitive dynamic with Crenessity, which is expected to enjoy a multi-year first-mover

advantage by the time atumelnant reaches the market. Nevertheless, if Ph 3 data confirm

the promising efficacy and safety profile observed in Ph 2, atumelnant could emerge as